CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
OPERATING EXPENSES
General and administrative	$ 241	$ 373	$ 1,265	$ 1,047
Research and development	175	865	808	2,667
Total operating expenses	416	1,238	2,073	3,714
Interest and other expenses (income), net	19	(4)	28	(67)
Loss from operations before taxes	435	1,234	2,101	3,647
Income tax benefit	0	0	(198)	0
NET LOSS	435	1,234	1,903	3,647
Less: Net Loss attributable to the noncontrolling interest	0	0	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 435	$ 1,234	$ 1,903	$ 3,647
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.01	$ 0.03	$ 0.05	$ 0.09
Basic and diluted shares outstanding (in shares)	40,885	40,885	40,885	40,885